Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2410402 | Vaccine | 2006 | 9 Pages |
Abstract
Conventional hepatitis B vaccines do not elicit adequate antibody production in 5–10% vaccinees. This trial tests the ability of a third-generation vaccine, containing PreS1 and PreS2 antigens in addition to the S antigen, to elicit seroprotective titres in documented non- and low-responders, compared with those to a conventional vaccine. In the primary population of non-responders (<10 IU/l anti-HBs antibodies after ≥4 previous injections of conventional vaccine) an enhanced antibody response was seen to additional injections of the third-generation vaccine compared with a conventional vaccine (absolute difference 14.9%; P = 0.006). Enhanced antibody responses were also found in a population that included low responders.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Pamela Rendi-Wagner, Daniel Shouval, Blaise Genton, Yoav Lurie, Hans Rümke, Greet Boland, Andreas Cerny, Markus Heim, Doris Bach, Manfred Schroeder, Herwig Kollaritsch,